OncoMed Pharmaceuticals Inc Form SC 13G/A February 14, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

OncoMed Pharmaceuticals, Inc.

(Name of Issuer)

common stock, par value \$0.001 per share

(Title of Class of Securities)

68234X 10 2

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Edgar Filing: OncoMed Pharmaceuticals Inc - Form SC 13G/A

Rule 13d-1(c)

Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1 NAMES OF REPORTING PERSONS

2	Perceptive CHECK T			ors LLC PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(a)	(b))					
3	SEC USE	Oì	NLY					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION							
	Delaware		5	SOLE VOTING POWER				
NU	UMBER OI	F						
	SHARES		6	0 SHARED VOTING POWER				
BEN	NEFICIALL	Y						
O	WNED BY	•		1,719,111				
	EACH		7	SOLE DISPOSITIVE POWER				
Rl	EPORTING	j						
	PERSON		8	0 SHARED DISPOSITIVE POWER				
	WITH:							
9	AGGREG	βAΊ	ΓΕ Α	1,719,111 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				

1,719,111

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.5%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IA

1 NAMES OF REPORTING PERSONS

Joseph Edelman	Jose	ph	Ede	elmar
----------------	------	----	-----	-------

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
 - (a) (b)
- 3 SEC USE ONLY
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America

5 SOLE VOTING POWER

NUMBER OF

SHARES

SHARED VOTING POWER

BENEFICIALLY

OWNED BY

1,719,111

EACH

7 SOLE DISPOSITIVE POWER

REPORTING

PERSON

0

8 SHARED DISPOSITIVE POWER

WITH:

1,719,111

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,719,111

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.5%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

1 NAMES OF REPORTING PERSONS

Perceptive Life Sciences Master Fund, Ltd.

- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
 - (a) (b)
- 3 SEC USE ONLY
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

5 SOLE VOTING POWER

NUMBER OF

SHARES

SHARED VOTING POWER

BENEFICIALLY

OWNED BY

1,719,111

EACH

7 SOLE DISPOSITIVE POWER

REPORTING

PERSON

0

8 SHARED DISPOSITIVE POWER

WITH:

1,719,111

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,719,111

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

4.5%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

Item 1(a). Name of Issuer:

OncoMed Pharmaceuticals, Inc. (the Issuer)

Item 1(b). Address of Issuer s Principal Executive Offices:

800 Chesapeake Drive

Redwood City, California 94063

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the Reporting Persons) are:

Perceptive Advisors LLC (Perceptive Advisors)

Joseph Edelman (Mr. Edelman)

Perceptive Life Sciences Master Fund, Ltd. (the Master Fund)

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor

New York, NY 10003

Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company

Mr. Edelman is a United States citizen

The Master Fund is a Cayman Islands corporation

Item 2(d). Title of Class of Securities:

common stock, par value \$0.001 per share (Common Stock)

Item 2(e). CUSIP Number:

68234X 10 2

Edgar Filing: OncoMed Pharmaceuticals Inc - Form SC 13G/A

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 38,630,145 outstanding shares of Common Stock, as reported in the Issuer s Form 10-Q filed on November 1, 2018.

The Master Fund directly holds 1,719,111 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on</u> by the Parent Holding Company or Control Person.

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2019

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

EXHIBIT 1

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 14, 2019

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member